Sanofi now expects 2023 business EPS to grow mid single-digit at CER, barring unforeseen major adverse events. Applying average July 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -6.5% to -7.5%. This upgrade includes approximately EUR 400 million of expected one-off COVID vaccine revenues in the second half of the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Sanofi-aventis (SNY) Q2 Earnings Cheat Sheet
- Sanofi enters strategic collaboration with Recludix Pharma
- AstraZeneca (NASDAQ:AZN) and Sanofi Secure FDA Green Light
- Sanofi, AstraZeneca confirm FDA approves Beyfortus for RSV disease in infants
- Sanofi, Scribe Therapeutics expand collaboration for in vivo genetic medicines